Over 450 studies conducted in pediatric, adult and elderly populations.

Elite Research Network is a group of investigative sites which specialize in conducting vaccine studies in all phases.  We recognize that most vaccine studies are unique due to thier rapid enrollment rates.  In order to recruit, screen and randomize a large number of study participants in a short amount of time while maintaining patient safety, our teams include investigators, study coordinators, patient recruiters, and dedicated EDC entry and quality assurance personnel.  Elite sites are held to the highest quality standards, allowing us to offer accelerated start-up, rapid enrollment and consistent quality across all studies.


Single point of contact 
Central IRB
One contract & budget
Master Service Agreement(s)
Study start-up in 30 days or less


Network-wide enrollment commitment
First patient in goal
350,000+ patient database
Data entry within 48 hours
98% retention rate


Standard CITI GCP training
100% QA on all study visits including Informed Consent
Query resolution with in 48 hours
Trained & experienced unblinded drug/dose verifiers


  • Author and present study reports
  • eSource experienced 
  • FWA Numbers
  • IBC-ready sites
  • Network recruitment manager
  • PBMC specimen collection & processing
  • Phase I-V
  • Protocol design and writing
  • Robust cold-chain management
  • Tropical and rare infectious disease
Our sites have successfully conducted the following vaccine studies:
  • Anthrax
  • Botulism
  • Cholera
  • Clostridium difficile
  • Dengue
  • E. Coli
  • Haemophilus (Hib)
  • Hepatitis
  • Herpes Zoster
  • HPV
  • H1N1 (Swine) Flu
  • H5N1 (Avian) Flu
  • Japanese Encephalitis
  • Meningococcal
  • Measles / Mumps / Rubella
  • Plague
  • Pneumonia (Pneumococcal)
  • Rabies
  • Ragweed
  • Rotavirus
  • RSV
  • Seasonal Influenza
  • Smallpox
  • Smoking Cessation
  • Strep B
  • Tetanus / Diphtheria / Pertussis
  • Travelers’ Diarrhea
  • Typhoid
  • West Nile Virus

Case Study # 1:

Sponsor conducted a 100-site elderly flu vaccine study. Twelve sites within the Elite Research Network were selected. Our sites enrolled an average of 99 participants per site, outperforming the average of 92 participants per site. A total of 1,188 participants were enrolled at our twelve sites with a collective retention rate of 98 percent.

Case Study # 2:

One of our sites was selected for a vaccine study for participants 65 years and older. The site, through its outsourced call center, made 575 calls and scheduled 189 patient visits. The site enrolled 147 subjects in three weeks, slowing down only because each site was limited to 60 randomized subjects per week. The site invoiced the sponsor $1,513 total, which resulted in a cost per randomized subject of $10.29.

Contact us for a complete list of vaccine enrollment metrics.

View our vaccine standards.
Call us: (843) 607-2933  |  email us:  |  follow us:    
Company            Investigator Sites            Therapeutic Expertise            Services            Phase I - IV            Library            News & Events            Contact